Medical News

RSS

Does too much texting puts teenagers at risk?

A seemingly harmless method of communication - text messaging on mobile phones could damage teenagers physically and psychologically a new study has revealed.

1 Jul 2010

Patel verdict “grossly inadequate”

Many including Queensland MP Rob Messenger, feel that the seven year sentence awarded to Dr. Jayant Patel by the Brisbane's Supreme Court yesterday is “grossly inadequate.” Patel was being tried for three cases of manslaughter and one case of grievous bodily injury during his tenure as Director of Surgery at Bundaberg Base hospital between 2003 and 2005.

1 Jul 2010

Wound Care Innovations signs distribution agreement with KOMED for CellerateRx

Wound Management Technologies, Inc. announced an important milestone in its planned growth strategy. Its wholly owned subsidiary Wound Care Innovations signed a distribution agreement with KOMED, LLC of Georgia for direct response advertising on television and niche online marketing of CellerateRx® in the United States.

1 Jul 2010

SAIC-Frederick, Fluidigm collaborate to decode entire genome of Epstein-Barr virus

SAIC-Frederick, Inc. and Fluidigm Corporation are collaborating to decode the entire genome of the Epstein-Barr virus (EBV) using technology that can speed up research on the genetic basis of cancer and other diseases.

1 Jul 2010

Fidelitone to provide logistics services for OROMed Healthcare

Fidelitone Logistics, an industry leader in third-party logistics and supply chain performance, has been selected to provide logistics services for OROMed Healthcare, a leading manufacturer of fully automatic, adjustable sleep systems.

1 Jul 2010

Diagnostic Hybrids receives Chinese SFDA approval for D3 Ultra DFA Respiratory Virus Screening and ID Kit

Diagnostic Hybrids, a Quidel Company, received approval from the People's Republic of China's State Food and Drug Administration (SFDA) for its D3 Ultra DFA Respiratory Virus Screening and ID Kit. The D3 Ultra DFA Respiratory Virus Screening and ID Kit is a direct fluorescence assay (DFA) that provides rapid, sensitive and specific screening and identification of Influenza A, Influenza B, Parainfluenza 1, 2, & 3, Respiratory Syncytial Virus and Adenovirus.

1 Jul 2010

Almost Family receives civil subpoena for documents and notice of investigation from SEC

Almost Family, Inc., a leading regional provider of home health nursing services, announced today that on June 30, 2010 it received a civil subpoena for documents and notice of investigation from the Securities and Exchange Commission.

1 Jul 2010

Hospira subsidiary completes tender offer for Javelin's outstanding shares of common stock

Hospira, Inc., a global specialty pharmaceutical and medication delivery company, today announced the successful completion of the tender offer by Discus Acquisition Corporation, a wholly owned Hospira subsidiary, to purchase all outstanding shares of the common stock of Javelin Pharmaceuticals, Inc..

1 Jul 2010

Advanced Life Sciences prices securities offering

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that it has established the pricing terms of its proposed offering of units.

1 Jul 2010

FIOCRUZ receives Brazil's Anvisa regulatory approval to market Chembio's Dual Path Platform HIV 1/2 rapid test

Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.

1 Jul 2010

Watson commences shipment of generic Exelon

Watson Pharmaceuticals, Inc. announced today that, under a settlement with Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Novartis AG, Novartis International Pharmaceutical Ltd., and Proterra AG (collectively "Novartis"), Watson has commenced shipment of a generic version of Exelon® (rivastigmine tartrate) 1.5mg, 3mg, 4.5mg and 6mg capsules. Exelon® is used to treat dementia in people with Alzheimer's disease.

1 Jul 2010

ThromboGenics to present microplasmin Phase III trial data at 28th ASRS and 10th EURETINA Congress

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that data from the second Phase III trial of microplasmin (TG-MV-007) for the non-surgical treatment of vitreomacular adhesion (VMA), are to be presented at the 28th Annual Meeting of the American Society of Retina Specialists (ASRS) and the 10th EURETINA Congress.

1 Jul 2010

AstraZeneca announces new support program for patients on ARIMIDEX

AstraZeneca today announced a new patient support program for postmenopausal women with hormone receptor-positive early breast cancer who are prescribed ARIMIDEX. The program is designed to provide eligible patients with instant discounts, potentially saving the patient up to $300.

1 Jul 2010

NHI closes $11.5M purchase/leaseback transaction with Bickford Senior Living

National Health Investors, Inc. announced today it has closed a $11.5 million purchase/leaseback transaction with Bickford Senior Living and its affiliates involving two assisted living facilities in Iowa and one in Indiana. The assisted living communities, two of which were built in 1998 and one in 2005, total 102 units and attract 100% private payment for services. The purchase price was funded from NHI's revolving credit facility.

1 Jul 2010

Düsseldorf court awards AGA Medical €2.1 million in Occlutech patent infringement case

AGA Medical Holdings, Inc. today announced the Düsseldorf Regional Court has awarded €2.1 million in damages to AGA Medical as a result of a patent infringement case filed by AGA Medical against Occlutech GmbH (Occlutech), based in Jena, Germany. AGA Medical is a leading developer of interventional devices for the minimally invasive treatment of structural heart defects and vascular abnormalities.

1 Jul 2010

Aptuit to acquire GSK's research business in Verona

GlaxoSmithKline (GSK) and Aptuit, Inc. announced today that they have finalized an agreement for Aptuit to acquire operations at GSK's Medicines Research Centre in Verona, Italy. The arrangement, which is effective as of July 1, 2010, provides for ongoing employment of the staff at the centre and for Aptuit to supply GSK with R&D services from the facilities. Financial terms have not been disclosed.

1 Jul 2010

IPC The Hospitalist Company acquires Austin Hospital Physicians

IPC The Hospitalist Company, Inc., a leading national hospitalist physician group practice company, announced today that it has acquired Austin Hospital Physicians, PA, (AHP) based in Austin, Texas. The acquisition represents a new market for IPC in Texas, adding to its well-established presence in the state. AHP has an annualized volume of approximately 9,000 patient encounters.

1 Jul 2010

IRIS submits 510(k) application for clearance of iChemVELOCITY and iRICELL Urinalysis Workstation

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Diagnostics Division submitted on June 30, 2010, a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for its iChem®Velocity™ Automated Urine Chemistry Analyzer and iRICELL® Urinalysis Workstation.

1 Jul 2010

Euthymics and DOV sign merger agreement

Euthymics Bioscience, Inc., a privately held Delaware corporation, and DOV Pharmaceutical, Inc., a Delaware corporation currently traded on the Pink Sheets, today jointly announced that they have signed a merger agreement in connection with the pending merger and acquisition of DOV by Euthymics.

1 Jul 2010

FDA grants Cyclacel's sapacitabine orphan drug designation for AML and MDS

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's sapacitabine (CYC682) product candidate for the treatment of both acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

1 Jul 2010

Medical News

Does too much texting puts teenagers at risk?

Patel verdict “grossly inadequate”

Wound Care Innovations signs distribution agreement with KOMED for CellerateRx

SAIC-Frederick, Fluidigm collaborate to decode entire genome of Epstein-Barr virus

Fidelitone to provide logistics services for OROMed Healthcare

Diagnostic Hybrids receives Chinese SFDA approval for D3 Ultra DFA Respiratory Virus Screening and ID Kit

Almost Family receives civil subpoena for documents and notice of investigation from SEC

Hospira subsidiary completes tender offer for Javelin's outstanding shares of common stock

Advanced Life Sciences prices securities offering

FIOCRUZ receives Brazil's Anvisa regulatory approval to market Chembio's Dual Path Platform HIV 1/2 rapid test

Watson commences shipment of generic Exelon

ThromboGenics to present microplasmin Phase III trial data at 28th ASRS and 10th EURETINA Congress

AstraZeneca announces new support program for patients on ARIMIDEX

NHI closes $11.5M purchase/leaseback transaction with Bickford Senior Living

Düsseldorf court awards AGA Medical €2.1 million in Occlutech patent infringement case

Aptuit to acquire GSK's research business in Verona

IPC The Hospitalist Company acquires Austin Hospital Physicians

IRIS submits 510(k) application for clearance of iChemVELOCITY and iRICELL Urinalysis Workstation

Euthymics and DOV sign merger agreement

FDA grants Cyclacel's sapacitabine orphan drug designation for AML and MDS

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News